Jaguar Health, Inc. fell 45.4% on Monday, November 2, 2026, on 2,203,492 shares. The headline around the move:
Jaguar Health, Inc. (JAGX:NASDAQ) closed at $0.884 on November 2, 2026, down 45.43% on the day. The stock trades 99.9% below its 52-week high of $1,102.50 and 9.1% above its 52-week low of $0.810. Over the past year, it lost 98.6%. Jaguar Health, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 249 trading sessions since October 31, 2025, JAGX closed higher on 88 days (35%). Its best day was January 16, 2026 (+86.93%) and its worst was September 23, 2026 (-74.14%). The stock moved 10% or more in a single session 56 times. It opened at least 5% above the previous day's high 3 times.
Jaguar Animal Health, Inc., an animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals, foals, and high value horses. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of chemotherapy-induced diarrhea and acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend for feline herpes and NP-500 for Type II diabetes and metabolic syndrome. The company was founded in 2013 and is headquartered in San Francisco, California.
Find more stocks like JAGX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.